Literature DB >> 18620738

Serum immunoglobulins and risk of infection: how low can you go?

Daniel E Furst1.   

Abstract

OBJECTIVES: To determine the relationship between the levels of serum immunoglobulin (Ig) levels and risk of infection. The following 2 main questions are addressed: (1) At what level do reduced serum concentrations of the different Ig species (focusing on IgA, IgG, and IgM) significantly increase the risk of infection above background and (2) For how long can Ig depletion be tolerated before an increased risk of infection becomes apparent.
METHODS: Information was gathered from a search of PubMed and relevant congress abstracts up to and including November 2007.
RESULTS: Sustained, very low levels of IgA, IgG, or IgM, as occur in primary immunodeficiency syndromes, are associated with significantly increased risks of infections, primarily respiratory tract infections of bacterial origin. Patients with IgG levels <100 mg/dL or IgM levels <20 mg/dL for prolonged periods have an increased risk of recurrent and sometimes life-threatening infectious episodes. Generally, IgA deficiency appears better tolerated. Replenishment of IgG in patients with hypogammaglobulinemia reduces the infection risk to background if IgG levels are maintained at approximately 500 mg/dL, although higher levels may be necessary in the presence of certain comorbidities. Transient depletion of IgG and/or IgM (or, less commonly, IgA) can occur in some patients following the administration of certain drugs, including anticonvulsants, corticosteroids, and rituximab. Available evidence suggests that such changes are not generally associated with an increased risk of infections.
CONCLUSIONS: While prolonged, very low levels of IgG and/or IgM are associated with a heightened risk of infections, transient or less severe immunodeficiency appears to be tolerated in most subjects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620738     DOI: 10.1016/j.semarthrit.2008.05.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  35 in total

1.  Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.

Authors:  Deborah A Zygmunt; Kelly E Crowe; Kevin M Flanigan; Paul T Martin
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

2.  Serum immunoglobulin G levels and peritonitis in peritoneal dialysis patients.

Authors:  Cécile Courivaud; Karine Bardonnet; Thomas Crepin; Catherine Bresson-Vautrin; Jean-Michel Rebibou; Didier Ducloux
Journal:  J Nephrol       Date:  2015-03-11       Impact factor: 3.902

3.  Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.

Authors:  Jeffrey S Stonebraker; Albert Farrugia; Benjamin Gathmann; Jordan S Orange
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

4.  Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases.

Authors:  Emilio Besada; Lucius Bader; Hans Nossent
Journal:  Rheumatol Int       Date:  2011-12-30       Impact factor: 2.631

Review 5.  Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

Authors:  Ewa Więsik-Szewczyk; Aleksandra Kucharczyk; Katarzyna Świerkocka; Elżbieta Rutkowska; Karina Jahnz-Różyk
Journal:  Clin Rheumatol       Date:  2017-05-09       Impact factor: 2.980

6.  Structural optimization of an aptamer generated from Ligand-Guided Selection (LIGS) resulted in high affinity variant toward mIgM expressed on Burkitt's lymphoma cell lines.

Authors:  Hasan E Zümrüt; Sana Batool; Nabeela Van; Shanell George; Sanam Bhandari; Prabodhika Mallikaratchy
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-03-29       Impact factor: 3.770

7.  Secondary Antibody Deficiency in Glucocorticoid Therapy Clearly Differs from Primary Antibody Deficiency.

Authors:  Clemens Wirsum; Cornelia Glaser; Sylvia Gutenberger; Baerbel Keller; Susanne Unger; Reinhard E Voll; Werner Vach; Thomas Ness; Klaus Warnatz
Journal:  J Clin Immunol       Date:  2016-03-15       Impact factor: 8.317

8.  Alterations in serum immunoglobulin levels in workers occupationally exposed to trichloroethylene.

Authors:  Luoping Zhang; Bryan A Bassig; Joseph L Mora; Roel Vermeulen; Yichen Ge; John D Curry; Wei Hu; Min Shen; Chuangyi Qiu; Zhiying Ji; Boris Reiss; Cliona M McHale; Songwang Liu; Weihong Guo; Mark P Purdue; Fei Yue; Laiyu Li; Martyn T Smith; Hanlin Huang; Xiaojiang Tang; Nathaniel Rothman; Qing Lan
Journal:  Carcinogenesis       Date:  2012-12-30       Impact factor: 4.944

Review 9.  B cells in the pathogenesis and treatment of rheumatoid arthritis.

Authors:  Bethany Marston; Arumugam Palanichamy; Jennifer H Anolik
Journal:  Curr Opin Rheumatol       Date:  2010-05       Impact factor: 5.006

10.  [Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].

Authors:  F Speth; N Wellinghausen; J-P Haas
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.